Compare FTHM & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTHM | PMN |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 23.5M |
| IPO Year | 2020 | N/A |
| Metric | FTHM | PMN |
|---|---|---|
| Price | $1.07 | $8.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.50 | ★ $72.67 |
| AVG Volume (30 Days) | ★ 95.6K | 43.4K |
| Earning Date | 11-11-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $421,612,000.00 | N/A |
| Revenue This Year | $30.07 | N/A |
| Revenue Next Year | $14.66 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.78 | N/A |
| 52 Week Low | $0.65 | $6.27 |
| 52 Week High | $3.37 | $39.75 |
| Indicator | FTHM | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 39.48 | 83.23 |
| Support Level | $1.16 | $7.35 |
| Resistance Level | $1.27 | $9.42 |
| Average True Range (ATR) | 0.07 | 0.68 |
| MACD | 0.00 | 0.18 |
| Stochastic Oscillator | 22.81 | 85.40 |
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.